Summit, AstraZeneca in talks over $15 billion cancer drug licensing deal, Bloomberg News reports

(Reuters) -AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as much as $15 billion, Bloomberg News reported on Thursday, citing people familiar with the matter. Shares of Summit Therapeutics surged 9.7% to $25.81 in morning trade. The Menlo Park, California-based drug developer did not immediately respond…

Read More